Figure 6
Study design: Phase I to assess SARS-CoV-2 seroprevalence and Phase II to assess humoral and cellular response to SARS-CoV-2 vaccine. IBD inflammatory bowel disease. TNF tumor necrosis factor.
Figure 6 | Scientific Reports
Study design: Phase I to assess SARS-CoV-2 seroprevalence and Phase II to assess humoral and cellular response to SARS-CoV-2 vaccine. IBD inflammatory bowel disease. TNF tumor necrosis factor.
